Nicole M. Verrills

This study evaluates (E,E)-bisantrene's anti-leukemic activity in AML by showing it suppresses MYC expression and induces apoptosis across multiple models.

This study shows bisantrene enhances the effectiveness of tyrosine kinase inhibitors in ccRCC by sustaining AKT inhibition and overcoming TKI resistance.

This study shows that hypomethylating agents induce epigenetic and transcriptional heterogeneity in AML cells, with some cells retaining methylation and showing increased self-renewal, and identifies statins as a potential co-treatment to enhance HMA efficacy.

This study identifies ATM-driven DNA repair and ROS addiction as mechanisms of resistance to FLT3 inhibitors in AML and shows ATM inhibition can overcome resistance in vitro and in vivo.

The paper introduces scTEM-seq to profile DNA methylation and transcriptomes in single cells, finding DNA methylation heterogeneity linked to gene expression and transposable element activity in AML cells.